Crossmark

Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial

Crossref DOI link: https://doi.org/10.1007/s00432-023-05103-4

Published Online: 2023-07-15

Published Print: 2023-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Qu, Aidong

Zhang, Shiying

Zou, Hongxia

Li, Sixiu

Chen, Dandan

Zhang, Yaowen

Li, Songsong

Zhang, Huijun

Yang, Ji

Yang, Yunkai

Huang, Yubao

Li, Xiuling

Zhang, Yuntao
License Information

Text and Data Mining valid from 2023-07-15

Version of Record valid from 2023-07-15
More Information

Article History

Received: 31 May 2023

Accepted: 30 June 2023

First Online: 15 July 2023

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

: This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was approved by the ethics committee of leading institution and agreed by other institution.

: Informed consent was obtained from all individual participants included in the study.

: Consent for publication has been obtained by the participants.

Document is current

Any future updates will be listed below